<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on April 20, 2026 at 9:28 PM by All in One SEO v4.9.6.2 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Thu, 16 Apr 2026 06:09:36 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/immutep-secures-fda-orphan-status-for-efti-in-sarcoma/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/immutep-secures-fda-orphan-status-for-efti-in-sarcoma/]]></link>
			<title>Immutep Secures FDA Orphan Status for Efti in Sarcoma</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 06:09:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/synthetic-design-lab-unveils-logic-gated-adc-platform/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/synthetic-design-lab-unveils-logic-gated-adc-platform/]]></link>
			<title>Synthetic Design Lab Unveils Logic-Gated ADC Platform</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 10:14:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/monopar-reports-phase-3-alxn1840-data-at-aan-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/monopar-reports-phase-3-alxn1840-data-at-aan-2026/]]></link>
			<title>Monopar Reports Phase 3 ALXN1840 Data at AAN 2026</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 10:03:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/epibiologics-doses-first-patient-in-epi-326-phase-1-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/epibiologics-doses-first-patient-in-epi-326-phase-1-study/]]></link>
			<title>EpiBiologics Doses First Patient in EPI-326 Phase 1 Study</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 09:50:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/nanobiotix-reports-nanoprimer-breakthrough-at-aacr-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/nanobiotix-reports-nanoprimer-breakthrough-at-aacr-2026/]]></link>
			<title>Nanobiotix Reports Nanoprimer Breakthrough at AACR 2026</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 09:25:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/philips-verida-ai-spectral-ct-wins-fda-510k-clearance/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/philips-verida-ai-spectral-ct-wins-fda-510k-clearance/]]></link>
			<title>Philips Verida AI Spectral CT Wins FDA 510(k) Clearance</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 07:14:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/leo-pharma-wins-china-approval-for-enstilar-psoriasis-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/leo-pharma-wins-china-approval-for-enstilar-psoriasis-drug/]]></link>
			<title>LEO Pharma Wins China Approval for Enstilar Psoriasis Drug</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 07:09:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/abbott-cancerguard-advances-multi-cancer-detection-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/abbott-cancerguard-advances-multi-cancer-detection-data/]]></link>
			<title>Abbott Cancerguard Advances Multi-Cancer Detection Data</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 07:03:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/piramal-ajinomoto-partner-to-boost-adc-manufacturing/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/piramal-ajinomoto-partner-to-boost-adc-manufacturing/]]></link>
			<title>Piramal, Ajinomoto Partner to Boost ADC Manufacturing</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:52:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/intelligent-bio-advances-fda-510k-with-cybersecurity/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/intelligent-bio-advances-fda-510k-with-cybersecurity/]]></link>
			<title>Intelligent Bio Advances FDA 510(k) with Cybersecurity</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:35:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/lilly-foundayo-shows-strong-phase-3-diabetes-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/lilly-foundayo-shows-strong-phase-3-diabetes-results/]]></link>
			<title>Lilly Foundayo Shows Strong Phase 3 Diabetes Results</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:25:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/gilead-secures-approvals-for-arcellx-acquisition-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/gilead-secures-approvals-for-arcellx-acquisition-deal/]]></link>
			<title>Gilead Secures Approvals for Arcellx Acquisition Deal</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:19:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/corify-care-gains-fda-clearance-for-acorys-4d-mapping/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/corify-care-gains-fda-clearance-for-acorys-4d-mapping/]]></link>
			<title>Corify Care Gains FDA Clearance for ACORYS 4D Mapping</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 06:09:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/xodus-medical-gains-fda-clearance-for-hot-pink-pad/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/xodus-medical-gains-fda-clearance-for-hot-pink-pad/]]></link>
			<title>Xodus Medical Gains FDA Clearance for Hot Pink Pad</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 05:28:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/kura-oncology-shows-strong-rcc-data-with-combo-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/kura-oncology-shows-strong-rcc-data-with-combo-therapy/]]></link>
			<title>Kura Oncology Shows Strong RCC Data with Combo Therapy</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 05:17:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/marengo-reports-phase-2-breast-cancer-data-at-aacr/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/marengo-reports-phase-2-breast-cancer-data-at-aacr/]]></link>
			<title>Marengo Reports Phase 2 Breast Cancer Data at AACR</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 05:08:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/merck-enflonsia-approved-in-eu-for-infant-rsv-protection/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/merck-enflonsia-approved-in-eu-for-infant-rsv-protection/]]></link>
			<title>Merck ENFLONSIA Approved in EU for Infant RSV Protection</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 04:58:17 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/nuvalent-zidesamtinib-shows-strong-nsclc-trial-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/nuvalent-zidesamtinib-shows-strong-nsclc-trial-results/]]></link>
			<title>Nuvalent Zidesamtinib Shows Strong NSCLC Trial Results</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 04:50:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/radiopharm-theranostics-advances-rad101-brain-imaging-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/radiopharm-theranostics-advances-rad101-brain-imaging-trial/]]></link>
			<title>Radiopharm Theranostics Advances RAD101 Brain Imaging Trial</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 04:43:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/city-of-hope-unveils-ai-and-cancer-breakthroughs-at-aacr/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/city-of-hope-unveils-ai-and-cancer-breakthroughs-at-aacr/]]></link>
			<title>City of Hope Unveils AI and Cancer Breakthroughs at AACR</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 10:52:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/aligos-amoytop-445m-hbv-licensing-deal-expands-access/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/aligos-amoytop-445m-hbv-licensing-deal-expands-access/]]></link>
			<title>Aligos-Amoytop $445M HBV Licensing Deal Expands Access</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:59:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/alkermes-reports-strong-phase-2-data-for-narcolepsy-drug/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/alkermes-reports-strong-phase-2-data-for-narcolepsy-drug/]]></link>
			<title>Alkermes Reports Strong Phase 2 Data for Narcolepsy Drug</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:49:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/janux-therapeutics-doses-first-patient-in-janx014-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/janux-therapeutics-doses-first-patient-in-janx014-study/]]></link>
			<title>Janux Therapeutics Doses First Patient in JANX014 Study</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:49:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/mapi-pharma-ga-depot-shows-strong-ms-progression-control/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/mapi-pharma-ga-depot-shows-strong-ms-progression-control/]]></link>
			<title>Mapi Pharma GA Depot Shows Strong MS Progression Control</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:39:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/aim-immunotech-advances-ampligen-phase-3-cancer-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/aim-immunotech-advances-ampligen-phase-3-cancer-trial/]]></link>
			<title>AIM ImmunoTech Advances Ampligen Phase 3 Cancer Trial</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:30:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/maia-activates-u-s-site-for-phase-2-lung-cancer-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/maia-activates-u-s-site-for-phase-2-lung-cancer-trial/]]></link>
			<title>MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:21:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/khondrion-doses-first-patient-in-phase-3-khenerfin-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/khondrion-doses-first-patient-in-phase-3-khenerfin-study/]]></link>
			<title>Khondrion Doses First Patient in Phase 3 KHENERFIN Study</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:26:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/leo-pharma-gains-fda-snda-acceptance-for-anzupgo/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/leo-pharma-gains-fda-snda-acceptance-for-anzupgo/]]></link>
			<title>LEO Pharma Gains FDA sNDA Acceptance for ANZUPGO</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:28:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/pharmather-peptide-policy-boosts-microneedle-strategy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/pharmather-peptide-policy-boosts-microneedle-strategy/]]></link>
			<title>PharmaTher Peptide Policy Boosts Microneedle Strategy</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:13:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/leadiant-biosciences-secures-canada-approval-for-cysklar/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/leadiant-biosciences-secures-canada-approval-for-cysklar/]]></link>
			<title>Leadiant Biosciences Secures Canada Approval for Cysklar</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:08:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/neurelis-shows-strong-seizure-control-data-for-valtoco-at-aan/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/neurelis-shows-strong-seizure-control-data-for-valtoco-at-aan/]]></link>
			<title>Neurelis Shows Strong Seizure Control Data for VALTOCO at AAN</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 09:00:37 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/bavarian-nordic-wins-swiss-approval-for-chikungunya-vaccine/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/bavarian-nordic-wins-swiss-approval-for-chikungunya-vaccine/]]></link>
			<title>Bavarian Nordic Wins Swiss Approval for Chikungunya Vaccine</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:06:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/boehringer-ingelheim-zongertinib-shows-strong-nsclc-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/boehringer-ingelheim-zongertinib-shows-strong-nsclc-results/]]></link>
			<title>Boehringer Ingelheim Zongertinib Shows Strong NSCLC Results</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 08:51:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/fate-therapeutics-ft839-car-t-shows-strong-preclinical-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/fate-therapeutics-ft839-car-t-shows-strong-preclinical-data/]]></link>
			<title>Fate Therapeutics FT839 CAR T Shows Strong Preclinical Data</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 08:50:38 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/covalon-advances-infection-prevention-and-wound-care/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/covalon-advances-infection-prevention-and-wound-care/]]></link>
			<title>Covalon Advances Infection Prevention and Wound Care</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:45:06 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/aop-health-wins-fda-approval-for-rapiblyk-in-pediatric-svt/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/aop-health-wins-fda-approval-for-rapiblyk-in-pediatric-svt/]]></link>
			<title>AOP Health Wins FDA Approval for Rapiblyk in Pediatric SVT</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:42:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/bioversys-starts-phase-3-bv100-pneumonia-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/bioversys-starts-phase-3-bv100-pneumonia-trial/]]></link>
			<title>BioVersys Starts Phase 3 BV100 Pneumonia Trial</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:33:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/foundation-medicine-expands-mrd-platform-with-saga-deal/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/foundation-medicine-expands-mrd-platform-with-saga-deal/]]></link>
			<title>Foundation Medicine Expands MRD Platform with SAGA Deal</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 08:32:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/eli-lilly-to-acquire-crossbridge-bio-for-adc-platform/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/eli-lilly-to-acquire-crossbridge-bio-for-adc-platform/]]></link>
			<title>Eli Lilly to Acquire CrossBridge Bio for ADC Platform</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 08:59:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/airs-medical-swiftmr-gains-fda-clearance-for-mri-ai/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/airs-medical-swiftmr-gains-fda-clearance-for-mri-ai/]]></link>
			<title>AIRS Medical SwiftMR Gains FDA Clearance for MRI AI</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 07:54:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/pds-biotech-reports-breakthrough-phase-2-mcrc-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/pds-biotech-reports-breakthrough-phase-2-mcrc-results/]]></link>
			<title>PDS Biotech Reports Breakthrough Phase 2 mCRC Results</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 09:52:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/savara-inc-gets-fda-extension-for-molgramostim-review/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/savara-inc-gets-fda-extension-for-molgramostim-review/]]></link>
			<title>Savara Inc. Gets FDA Extension for Molgramostim Review</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 08:52:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/boehringer-ingelheim-zai-lab-advance-dll3-cancer-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/boehringer-ingelheim-zai-lab-advance-dll3-cancer-trial/]]></link>
			<title>Boehringer Ingelheim, Zai Lab Advance DLL3 Cancer Trial</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 08:44:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/tempus-ai-predicta-expand-genomics-test-for-blood-cancer/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/tempus-ai-predicta-expand-genomics-test-for-blood-cancer/]]></link>
			<title>Tempus AI, Predicta Expand Genomics Test for Blood Cancer</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 08:39:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/cala-health-gains-fda-clearance-for-kiq-plus-device/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/cala-health-gains-fda-clearance-for-kiq-plus-device/]]></link>
			<title>Cala Health Gains FDA Clearance for kIQ Plus Device</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 08:25:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/precision-biosciences-expands-eliminate-b-trial-in-eu/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/precision-biosciences-expands-eliminate-b-trial-in-eu/]]></link>
			<title>Precision BioSciences Expands ELIMINATE-B Trial in EU</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 08:14:27 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/organon-vtama-cream-gains-strong-aad-guideline-support/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/organon-vtama-cream-gains-strong-aad-guideline-support/]]></link>
			<title>Organon VTAMA Cream Gains Strong AAD Guideline Support</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 06:36:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/dogwood-secures-fda-ind-nod-for-sp16-pain-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/dogwood-secures-fda-ind-nod-for-sp16-pain-therapy/]]></link>
			<title>Dogwood Secures FDA IND Nod for SP16 Pain Therapy</title>
			<pubDate><![CDATA[Thu, 16 Apr 2026 06:19:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/interna-daiichi-sankyo-partner-on-drug-delivery-tech/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/interna-daiichi-sankyo-partner-on-drug-delivery-tech/]]></link>
			<title>Interna, Daiichi Sankyo Partner on Drug Delivery Tech</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 07:38:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/geminii-shows-promising-nsclc-data-for-bioelectronic-therapy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/geminii-shows-promising-nsclc-data-for-bioelectronic-therapy/]]></link>
			<title>Geminii Shows Promising NSCLC Data for Bioelectronic Therapy</title>
			<pubDate><![CDATA[Fri, 17 Apr 2026 07:21:30 +0000]]></pubDate>
		</item>
				</channel>
</rss>
